Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2007

01.09.2007 | Clinical Epidemiology

Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

verfasst von: Jane C. Figueiredo, Marguerite Ennis, Julia A. Knight, John R. McLaughlin, Nicky Hood, Frances O’Malley, Irene L. Andrulis, Pamela J. Goodwin

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study was to examine the association of: (i) diagnosis at age ≤35, (ii) first-degree family history of breast or ovarian cancer (BOC) and (iii) a research based definition of genetic risk, with tumor characteristics, treatment and survival in breast cancer (BC).

Patients and methods

Consenting female participants in the population-based Ontario Familial Breast Cancer Registry diagnosed with primary invasive BC between 1996 and 1998 were followed prospectively until 2005.

Results

Among 967 women, 105 were ≤35 years old at diagnosis and 686 were classified as genetic risk cases, including 349 with a first-degree family history. Individuals diagnosed at age ≤35 were more likely to self-detect tumors, to present with inflammatory BC, to have invasive ductal carcinoma of no special type, high T stage, and tumors with lymphovascular invasion (LVI), high grade and negative estrogen receptors. Younger women were more likely to receive chemotherapy and less likely to receive hormonal therapy. Diagnosis ≤35 years old was associated with significantly reduced distant recurrence free survival, an effect that did not persist after adjustment for tumor and treatment related variables. Poor outcomes were restricted to younger women with hormone responsive BC. Family history was associated with increased rates of mammographic detection of BC, lower tumor stage and less frequent inflammatory BC, but had no association with BC outcomes.

Conclusion

Women diagnosed with BC at age ≤35 have more aggressive tumors; these adverse tumor characteristics, rather than age, lead to poor outcomes. Family history was not associated with survival.
Literatur
1.
Zurück zum Zitat Ruder AM, Moodie PF, Nelson NA, Choi NW (1988) Does family history of breast cancer improve survival among patients with breast cancer? Am J Obstet Gynecol 158:963–968PubMed Ruder AM, Moodie PF, Nelson NA, Choi NW (1988) Does family history of breast cancer improve survival among patients with breast cancer? Am J Obstet Gynecol 158:963–968PubMed
2.
Zurück zum Zitat Israeli D, Tartter PI, Brower ST, Mizrachy B, Bratton J (1994) The significance of family history for patients with carcinoma of the breast. J Am Coll Surg 179:29–32PubMed Israeli D, Tartter PI, Brower ST, Mizrachy B, Bratton J (1994) The significance of family history for patients with carcinoma of the breast. J Am Coll Surg 179:29–32PubMed
3.
Zurück zum Zitat Jobsen JJ, Meerwaldt JH, van der Palen J (2000) Family history in breast cancer is not a prognostic factor? Breast 9:83–87PubMedCrossRef Jobsen JJ, Meerwaldt JH, van der Palen J (2000) Family history in breast cancer is not a prognostic factor? Breast 9:83–87PubMedCrossRef
4.
Zurück zum Zitat Russo A, Herd-Smith A, Gestri D, Bianchi S, Vezzosi V, Rosselli Del Turco M, Cardona G (2002) Does family history influence survival in breast cancer cases? Int J Cancer 99:427–430PubMedCrossRef Russo A, Herd-Smith A, Gestri D, Bianchi S, Vezzosi V, Rosselli Del Turco M, Cardona G (2002) Does family history influence survival in breast cancer cases? Int J Cancer 99:427–430PubMedCrossRef
5.
Zurück zum Zitat Molino A, Giovannini M, Pedersini R, Frisinghelli M, Micciolo R, Mandara M, Pavarana M, Cetto GL (2004) Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91:96–98PubMedCrossRef Molino A, Giovannini M, Pedersini R, Frisinghelli M, Micciolo R, Mandara M, Pavarana M, Cetto GL (2004) Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91:96–98PubMedCrossRef
6.
Zurück zum Zitat Verkooijen HM, Chappuis PO, Rapiti E, Vlastos G, Fioretta G, Sarp S, Sappino AP, Schubert H, Bouchardy C (2006) Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer 94:231–238PubMedCrossRef Verkooijen HM, Chappuis PO, Rapiti E, Vlastos G, Fioretta G, Sarp S, Sappino AP, Schubert H, Bouchardy C (2006) Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer 94:231–238PubMedCrossRef
7.
Zurück zum Zitat Fukutomi T, Kobayashi Y, Nanasawa T, Yamamoto H, Tsuda H (1993) A clinicopathological analysis of breast cancer in patients with a family history. Surg Today 23:849–854PubMedCrossRef Fukutomi T, Kobayashi Y, Nanasawa T, Yamamoto H, Tsuda H (1993) A clinicopathological analysis of breast cancer in patients with a family history. Surg Today 23:849–854PubMedCrossRef
8.
Zurück zum Zitat Mohammed SN, Smith P, Hodgson SV, Fentiman IS, Miles DW, Barnes DM, Millis RR, Rubens RD (1998) Family history and survival in premenopausal breast cancer. Br J Cancer 77:2252–2256PubMed Mohammed SN, Smith P, Hodgson SV, Fentiman IS, Miles DW, Barnes DM, Millis RR, Rubens RD (1998) Family history and survival in premenopausal breast cancer. Br J Cancer 77:2252–2256PubMed
9.
Zurück zum Zitat Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151:703–714PubMed Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151:703–714PubMed
10.
Zurück zum Zitat Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, Petty PM, Donohue JH, Grant CS, Sloan JA, Sellers TA, Hartmann LC (2005) Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23:7849–7856PubMedCrossRef Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, Petty PM, Donohue JH, Grant CS, Sloan JA, Sellers TA, Hartmann LC (2005) Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23:7849–7856PubMedCrossRef
11.
Zurück zum Zitat Thalib L, Wedren S, Granath F, Adami HO, Rydh B, Magnusson C, Hall P (2004) Breast cancer prognosis in relation to family history of breast and ovarian cancer. Br J Cancer 90:1378–1381PubMedCrossRef Thalib L, Wedren S, Granath F, Adami HO, Rydh B, Magnusson C, Hall P (2004) Breast cancer prognosis in relation to family history of breast and ovarian cancer. Br J Cancer 90:1378–1381PubMedCrossRef
12.
Zurück zum Zitat Schouten LJ, Hupperets PS, Jager JJ, Volovics L, Wils JA, Verbeek AL, Blijham GH (1997) Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 43:217–223PubMedCrossRef Schouten LJ, Hupperets PS, Jager JJ, Volovics L, Wils JA, Verbeek AL, Blijham GH (1997) Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 43:217–223PubMedCrossRef
13.
Zurück zum Zitat Malone KE, Daling JR, Weiss NS, McKnight B, White E, Voigt LF (1996) Family history and survival of young women with invasive breast carcinoma. Cancer 78:1417–1425PubMedCrossRef Malone KE, Daling JR, Weiss NS, McKnight B, White E, Voigt LF (1996) Family history and survival of young women with invasive breast carcinoma. Cancer 78:1417–1425PubMedCrossRef
14.
Zurück zum Zitat Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nole F, Martinelli G, Goldhirsch A (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279PubMedCrossRef Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R, Catalano G, Galimberti V, Nole F, Martinelli G, Goldhirsch A (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279PubMedCrossRef
15.
Zurück zum Zitat Shannon C, Smith IE (2003) Breast cancer in adolescents and young women. Eur J Cancer 39:2632–2642PubMedCrossRef Shannon C, Smith IE (2003) Breast cancer in adolescents and young women. Eur J Cancer 39:2632–2642PubMedCrossRef
16.
Zurück zum Zitat Walker RA, Lees E, Webb MB, Dearing SJ (1996) Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 74:1796–1800PubMed Walker RA, Lees E, Webb MB, Dearing SJ (1996) Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 74:1796–1800PubMed
17.
Zurück zum Zitat Winchester DP, Osteen RT, Menck HR (1996) The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 78:1838–1843PubMedCrossRef Winchester DP, Osteen RT, Menck HR (1996) The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 78:1838–1843PubMedCrossRef
18.
Zurück zum Zitat Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW (1997) Early-onset breast cancer—histopathological and prognostic considerations. Br J Cancer 75:1318–1323PubMed Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW (1997) Early-onset breast cancer—histopathological and prognostic considerations. Br J Cancer 75:1318–1323PubMed
19.
Zurück zum Zitat Chung M, Chang HR, Bland KI, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77:97–103PubMedCrossRef Chung M, Chang HR, Bland KI, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77:97–103PubMedCrossRef
20.
Zurück zum Zitat Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563PubMedCrossRef Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563PubMedCrossRef
21.
Zurück zum Zitat Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474–478PubMedCrossRef Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320:474–478PubMedCrossRef
22.
Zurück zum Zitat Han W, Kim SW, Park IA, Kang D, Youn YK, Oh SK, Choe KJ, Noh DY (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82PubMedCrossRef Han W, Kim SW, Park IA, Kang D, Youn YK, Oh SK, Choe KJ, Noh DY (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82PubMedCrossRef
23.
Zurück zum Zitat (2001) Consensus conference 2000: adjuvant therapy for breast cancer. National Institutes of Health Consensus Development Conference Statement November 1–3, 2000. Cancer Control 8:55 (2001) Consensus conference 2000: adjuvant therapy for breast cancer. National Institutes of Health Consensus Development Conference Statement November 1–3, 2000. Cancer Control 8:55
24.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817–3827PubMed Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817–3827PubMed
25.
Zurück zum Zitat Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L (1995) Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 62:138–144PubMedCrossRef Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L (1995) Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 62:138–144PubMedCrossRef
26.
Zurück zum Zitat Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P, Sappino AP, Kurtz J, Neyroud-Caspar I, Bouchardy C (2005) Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer 41:1446–1452PubMedCrossRef Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P, Sappino AP, Kurtz J, Neyroud-Caspar I, Bouchardy C (2005) Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer 41:1446–1452PubMedCrossRef
27.
Zurück zum Zitat Merchant TE, McCormick B, Yahalom J, Borgen P (1996) The influence of older age on breast cancer treatment decisions and outcome. Int J Radiat Oncol Biol Phys 34:565–570PubMed Merchant TE, McCormick B, Yahalom J, Borgen P (1996) The influence of older age on breast cancer treatment decisions and outcome. Int J Radiat Oncol Biol Phys 34:565–570PubMed
28.
Zurück zum Zitat Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30:44–51 Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30:44–51
29.
Zurück zum Zitat Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874PubMedCrossRef Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355:1869–1874PubMedCrossRef
30.
Zurück zum Zitat Andrulis IL, Boyd NF, Sutherland H (1997) New Ontario familial breast cancer registry to facilitate genetic and epidemiologic studies. Can Fam Physician 43:949–950PubMed Andrulis IL, Boyd NF, Sutherland H (1997) New Ontario familial breast cancer registry to facilitate genetic and epidemiologic studies. Can Fam Physician 43:949–950PubMed
31.
Zurück zum Zitat John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O’Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D (2004) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:R375–R389PubMedCrossRef John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O’Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D (2004) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:R375–R389PubMedCrossRef
32.
Zurück zum Zitat Sutherland HJ, Lacroix J, Knight J, Andrulis IL, Boyd NF (2001) The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario. J Clin Epidemiol 54:93–98PubMedCrossRef Sutherland HJ, Lacroix J, Knight J, Andrulis IL, Boyd NF (2001) The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario. J Clin Epidemiol 54:93–98PubMedCrossRef
33.
Zurück zum Zitat Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL (2002) Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. Ann Epidemiol 12:27–33PubMedCrossRef Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL (2002) Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. Ann Epidemiol 12:27–33PubMedCrossRef
34.
Zurück zum Zitat Holowaty EJ, Marrett LD, Fehringer G (1995) Cancer incidence in Ontario trends and regional variations. The Ontario Cancer Treatment and Research Foundation, Toronto Holowaty EJ, Marrett LD, Fehringer G (1995) Cancer incidence in Ontario trends and regional variations. The Ontario Cancer Treatment and Research Foundation, Toronto
35.
Zurück zum Zitat Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, Catelano E, Hendrickson MR, Hibshoosh H, Layfield LJ, Memeo L, Wu H, O’Malley FP (2006). Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19:195–207PubMedCrossRef Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, Catelano E, Hendrickson MR, Hibshoosh H, Layfield LJ, Memeo L, Wu H, O’Malley FP (2006). Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19:195–207PubMedCrossRef
36.
Zurück zum Zitat Malone KE, Daling JR, Thompson JD, O’Brien CA, Francisco LV, Ostrander EA (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922–929PubMedCrossRef Malone KE, Daling JR, Thompson JD, O’Brien CA, Francisco LV, Ostrander EA (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922–929PubMedCrossRef
37.
Zurück zum Zitat Haffty BG, Silber A, Matloff E, Chung J, Lannin D (2006) Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet 43:133–137PubMedCrossRef Haffty BG, Silber A, Matloff E, Chung J, Lannin D (2006) Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet 43:133–137PubMedCrossRef
38.
Zurück zum Zitat (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717 (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
39.
Zurück zum Zitat Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 24:1332–1341PubMedCrossRef Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol 24:1332–1341PubMedCrossRef
40.
Zurück zum Zitat Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, Wilson PW (2001) Family breast cancer history and mammography: Framingham Offspring Study. Am J Epidemiol 154:916–923PubMedCrossRef Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, Wilson PW (2001) Family breast cancer history and mammography: Framingham Offspring Study. Am J Epidemiol 154:916–923PubMedCrossRef
41.
Zurück zum Zitat Madlensky L, Vierkant RA, Vachon CM, Pankratz VS, Cerhan JR, Vadaparampil ST, Sellers TA (2005) Preventive health behaviors and familial breast cancer. Cancer Epidemiol Biomarkers Prev 14:2340–2345PubMedCrossRef Madlensky L, Vierkant RA, Vachon CM, Pankratz VS, Cerhan JR, Vadaparampil ST, Sellers TA (2005) Preventive health behaviors and familial breast cancer. Cancer Epidemiol Biomarkers Prev 14:2340–2345PubMedCrossRef
42.
Zurück zum Zitat Groenendijk RP, Rombouts MC, Ruers TJ, Boetes C, Wobbes T (2002) Breast cancer screening: using familiality for earlier detection. Breast 11:116–119PubMedCrossRef Groenendijk RP, Rombouts MC, Ruers TJ, Boetes C, Wobbes T (2002) Breast cancer screening: using familiality for earlier detection. Breast 11:116–119PubMedCrossRef
43.
Zurück zum Zitat Audrain-McGovern J, Hughes C, Patterson F (2003) Effecting behavior change: awareness of family history. Am J Prev Med 24:183–189PubMedCrossRef Audrain-McGovern J, Hughes C, Patterson F (2003) Effecting behavior change: awareness of family history. Am J Prev Med 24:183–189PubMedCrossRef
44.
Zurück zum Zitat Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003PubMedCrossRef Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003PubMedCrossRef
45.
Zurück zum Zitat Slattery ML, Berry TD, Kerber RA (1993) Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? Epidemiology 4:543–548PubMedCrossRef Slattery ML, Berry TD, Kerber RA (1993) Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? Epidemiology 4:543–548PubMedCrossRef
46.
Zurück zum Zitat James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24:707–715PubMedCrossRef James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24:707–715PubMedCrossRef
47.
Zurück zum Zitat Mancuso C, Glendon G, Anson-Cartwright L, Shi EJ, Andrulis I, Knight J (2004) Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Ann Epidemiol 14:36–43PubMedCrossRef Mancuso C, Glendon G, Anson-Cartwright L, Shi EJ, Andrulis I, Knight J (2004) Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Ann Epidemiol 14:36–43PubMedCrossRef
48.
Zurück zum Zitat Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725PubMedCrossRef Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725PubMedCrossRef
49.
Zurück zum Zitat Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143–1148PubMedCrossRef Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H (2000) Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36:1143–1148PubMedCrossRef
50.
Zurück zum Zitat Murff HJ, Byrne D, Syngal S (2004) Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med 27:239–245PubMed Murff HJ, Byrne D, Syngal S (2004) Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med 27:239–245PubMed
51.
Zurück zum Zitat Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef
Metadaten
Titel
Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study
verfasst von
Jane C. Figueiredo
Marguerite Ennis
Julia A. Knight
John R. McLaughlin
Nicky Hood
Frances O’Malley
Irene L. Andrulis
Pamela J. Goodwin
Publikationsdatum
01.09.2007
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9433-3

Weitere Artikel der Ausgabe 1/2007

Breast Cancer Research and Treatment 1/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.